PURPOSE: Multiple studies have demonstrated the negative impact of cancer care delays during the COVID-19 pandemic, and transmission mitigation techniques are imperative for continued cancer care delivery. We aimed to gauge the effectiveness of these measures at the University of Pennsylvania. METHODS: We conducted a longitudinal study of SARS-CoV-2 antibody seropositivity and seroconversion in patients presenting to infusion centers for cancer-directed therapy between May 21, 2020, and October 8, 2020. Participants completed questionnaires and had up to five serial blood collections. RESULTS: Of 124 enrolled patients, only two (1.6%) had detectable SARS-CoV-2 antibodies on initial blood draw, and no initially seronegative patients developed newly detectable antibodies on subsequent blood draw(s), corresponding to a seroconversion rate of 0% (95% CI, 0.0 TO 4.1%) over 14.8 person-years of follow up, with a median of 13 health care visits per patient. CONCLUSION: These results suggest that patients with cancer receiving in-person care at a facility with aggressive mitigation efforts have an extremely low likelihood of COVID-19 infection.
PURPOSE: Multiple studies have demonstrated the negative impact of cancer care delays during the COVID-19 pandemic, and transmission mitigation techniques are imperative for continued cancer care delivery. We aimed to gauge the effectiveness of these measures at the University of Pennsylvania. METHODS: We conducted a longitudinal study of SARS-CoV-2 antibody seropositivity and seroconversion in patients presenting to infusion centers for cancer-directed therapy between May 21, 2020, and October 8, 2020. Participants completed questionnaires and had up to five serial blood collections. RESULTS: Of 124 enrolled patients, only two (1.6%) had detectable SARS-CoV-2 antibodies on initial blood draw, and no initially seronegative patients developed newly detectable antibodies on subsequent blood draw(s), corresponding to a seroconversion rate of 0% (95% CI, 0.0 TO 4.1%) over 14.8 person-years of follow up, with a median of 13 health care visits per patient. CONCLUSION: These results suggest that patients with cancer receiving in-person care at a facility with aggressive mitigation efforts have an extremely low likelihood of COVID-19 infection.
Authors: Alex Broom; Katherine Kenny; Alexander Page; Nicole Cort; Eric S Lipp; Aaron C Tan; David M Ashley; Kyle M Walsh; Mustafa Khasraw Journal: Clin Cancer Res Date: 2020-08-18 Impact factor: 12.531
Authors: Luis Cabezón-Gutiérrez; Sara Custodio-Cabello; Magda Palka-Kotlowska; Eduardo Oliveros-Acebes; María José García-Navarro; Parham Khosravi-Shahi Journal: Cancer Treat Rev Date: 2020-09-01 Impact factor: 12.111
Authors: Leticia Kuri-Cervantes; M Betina Pampena; Wenzhao Meng; Aaron M Rosenfeld; Caroline A G Ittner; Ariel R Weisman; Roseline S Agyekum; Divij Mathew; Amy E Baxter; Laura A Vella; Oliva Kuthuru; Sokratis A Apostolidis; Luanne Bershaw; Jeanette Dougherty; Allison R Greenplate; Ajinkya Pattekar; Justin Kim; Nicholas Han; Sigrid Gouma; Madison E Weirick; Claudia P Arevalo; Marcus J Bolton; Eileen C Goodwin; Elizabeth M Anderson; Scott E Hensley; Tiffanie K Jones; Nilam S Mangalmurti; Eline T Luning Prak; E John Wherry; Nuala J Meyer; Michael R Betts Journal: Sci Immunol Date: 2020-07-15
Authors: Dustin D Flannery; Sigrid Gouma; Miren B Dhudasia; Sagori Mukhopadhyay; Madeline R Pfeifer; Emily C Woodford; Jeffrey S Gerber; Claudia P Arevalo; Marcus J Bolton; Madison E Weirick; Eileen C Goodwin; Elizabeth M Anderson; Allison R Greenplate; Justin Kim; Nicholas Han; Ajinkya Pattekar; Jeanette Dougherty; Oliva Kuthuru; Divij Mathew; Amy E Baxter; Laura A Vella; JoEllen Weaver; Anurag Verma; Rita Leite; Jeffrey S Morris; Daniel J Rader; Michal A Elovitz; E John Wherry; Karen M Puopolo; Scott E Hensley Journal: Sci Immunol Date: 2020-07-29
Authors: Elizabeth M Anderson; Eileen C Goodwin; Anurag Verma; Claudia P Arevalo; Marcus J Bolton; Madison E Weirick; Sigrid Gouma; Christopher M McAllister; Shannon R Christensen; JoEllen Weaver; Philip Hicks; Tomaz B Manzoni; Oluwatosin Oniyide; Holly Ramage; Divij Mathew; Amy E Baxter; Derek A Oldridge; Allison R Greenplate; Jennifer E Wu; Cécile Alanio; Kurt D'Andrea; Oliva Kuthuru; Jeanette Dougherty; Ajinkya Pattekar; Justin Kim; Nicholas Han; Sokratis A Apostolidis; Alex C Huang; Laura A Vella; Leticia Kuri-Cervantes; M Betina Pampena; Michael R Betts; E John Wherry; Nuala J Meyer; Sara Cherry; Paul Bates; Daniel J Rader; Scott E Hensley Journal: Cell Date: 2021-02-09 Impact factor: 41.582
Authors: L Zhang; F Zhu; L Xie; C Wang; J Wang; R Chen; P Jia; H Q Guan; L Peng; Y Chen; P Peng; P Zhang; Q Chu; Q Shen; Y Wang; S Y Xu; J P Zhao; M Zhou Journal: Ann Oncol Date: 2020-03-26 Impact factor: 32.976
Authors: Thorsten Fuereder; Anna Sophie Berghoff; Gerwin Heller; Helmuth Haslacher; Thomas Perkmann; Robert Strassl; Julia Maria Berger; Hannah Christina Puhr; Judith Kreminger; Florian Moik; Lorenz Schubert; Angelika Martina Starzer; Ariane Steindl; Stefan Winkler; Matthias Preusser; Selma Tobudic Journal: ESMO Open Date: 2020-09
Authors: Georg Pfeiler; Angela DeMichele; Amylou C Dueck; Christian Fesl; Michael Gnant; Erica L Mayer Journal: Lancet Oncol Date: 2022-02 Impact factor: 41.316